Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

PURPOSE: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. PATIENTS AND METHODS: Patients were randomly assigned (1:1) to receive MYL-140...

Descripción completa

Detalles Bibliográficos
Autores principales: Socinski, Mark A., Waller, Cornelius F., Idris, Tazeen, Bondarenko, Igor, Luft, Alexander, Beckmann, Katrin, Vishweswaramurthy, Ashwini, Loganathan, Subramanian, Donnelly, Charles, Hummel, Matthew A., Shapiro, Roxann, Woods, Melody, Rao, Anita, Nayak, Vivek G, Ranganna, Gopinath, Barve, Abhijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606731/
https://www.ncbi.nlm.nih.gov/pubmed/34819997
http://dx.doi.org/10.1177/17588359211045845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606731/
https://www.ncbi.nlm.nih.gov/pubmed/34819997
http://dx.doi.org/10.1177/17588359211045845

Ejemplares similares